KFAR SABA, ISRAEL--(Marketwired - Feb 13, 2014) - Ornim Medical, Inc., a biomedical technology company pioneering non-invasive patient monitoring solutions for cerebral and tissue blood flow, announced today that new study results demonstrate the feasibility of the CerOx cerebral oxidation monitor for measuring regional cerebral tissue oxygenation in patients with severe traumatic brain injury. The study is currently available online in the Journal of Neurosurgery, the official journal of the American Association of Neurological Surgeons.

The CerOx monitor employs Ornim Medical's patented UTLight™ technology, which utilizes weak acoustic beams to identify light emerging from deep tissue layers. UTLight harnesses the ability of near-infrared light to measure regional oxygen saturation in combination with ultrasound that can achieve localization via the acousto-optic effect. The CerOx monitor is the only FDA-cleared device enabling continuous, non-invasive measurement of blood flow and oxygen saturation in real time.

"CerOx represents a major advance in the care of patients with traumatic brain injury," said Daryl R. Gress, MD, Associate Professor of Neurology and Neurosurgery Director of Neurocritical Care, University of Virginia. "Measuring both blood flow and oxygen saturation in real time allows neurointensivists and neurosurgeons to act quickly and decisively to optimize hemodynamics, blood pressure and intracranial pressure management strategies in the critical care setting." 

Eighteen patients with severe traumatic brain injury admitted to the intensive care unit requiring intracranial pressure monitoring and advanced neuromonitoring were included in the study. The authors found a strong correlation (r = 0.60, p < 0.001) between the jugular bulb venous saturation from the venous blood gas and the CerOx measure of regional cerebral tissue saturation on the side ipsilateral to the catheter. A multivariate analysis revealed that among the physiological parameters of mean arterial blood pressure, ICP, brain tissue oxygen tension, and CerOx measurements on the ipsilateral and contralateral sides, only ipsilateral CerOx measurements were significantly correlated to jugular bulb venous saturation (p < 0.001). The authors concluded that the correlation between the CerOx measurements and the jugular bulb venous measurements of oxygen saturation indicate that the CerOx may be able to provide an estimation of cerebral oxygenation status in a noninvasive manner.

"Our lead products, CerOx and c-FLOW™, are designed to address critical unmet needs in the care of patients with neurological injuries and these results add to the emerging evidence supporting the clinical potential of CerOx," said Israel Schreiber, chief executive officer of Ornim Medical. "The response we have received from neurosurgeons and healthcare professionals at our CerOx test sites has been overwhelmingly positive and we look forward to further collaboration with the neurology community as we work to integrate noninvasive monitoring of blood flow and oxygen saturation into clinical practice across the globe."

Visit Ornim Medical at the 2014 International Stroke Conference

Healthcare professionals can learn more about CerOx and other technological innovations from Ornim Medical at the American Heart Association's 2014 International Stroke Conference, from February 12-14, 2014, in San Diego, California. Ornim Medical is located at booth 526.

About Ornim Medical

Ornim Medical is a biomedical technology company specializing in clinical research, development, and distribution of the highest quality monitoring devices for cerebral and tissue blood flow. Its two products, the CerOx™ and the c-FLOW™ are based on the patented UTLight™ technology and can be used in most areas where cerebral blood flow needs to be monitored.

Ornim Medical provides physicians with the most advanced monitoring tools to help direct safe and decisive patient care when the perfusion of vital tissue is at stake. Ornim's CerOx™ monitor is the only device enabling simultaneous, non-invasive measurement of blood flow and oxygen saturation, while the c-FLOW™ is a pared down version used to measure cerebral blood flow only. The use of either of these products (depending on the clinical setting) provide physicians with critical information needed to understand perfusion, helping direct treatment and lower the cost of patient care.

Ornim Medical's patented UTLight™ technology employs the combination of light and ultrasound to provide a non-invasive measure of regional blood oxygen saturation and blood flow. UTLight™ technology is unique among all other commercially available NIRS technologies, since it also analyzes the light speckle signal and does not rely solely on the intensity of light reaching the detector.

Ornim Medical's unique technology is protected by 13 granted worldwide patents.

Contact Information:

For media inquiries, please contact:
Christopher Frates
Lazar Partners